The difference between adalimumab and tocilizumab

Adalimumab and tocilizumab are two commonly used biologics used to treat autoimmune diseases. Adalimumab is a TNF-α (tumor necrosis factor-α) inhibitor that inhibits the inflammatory response by binding to and neutralizing TNF-α; and tocilizumab is an IL-23 (interleukin-23) antagonist that modulates the immune response by inhibiting the action of IL-23. Adalimumab is approved to treat a variety of autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn's disease. Tocilizumab is mainly used to treat moderate to severe psoriasis, psoriatic arthritis and spondyloarthritis.